AstraZeneca vs United Airlines: Founders, CEOs and History
AstraZeneca was founded in 1999 by Sir David Barnes, Håkan Mogren and is led by Pascal Soriot. United Airlines was founded in 1926 by Walter T. Varney, William Boeing and is led by Scott Kirby.
Company facts
AstraZeneca
- Founded
- 1999
- Headquarters
- Cambridge, England
- Current CEO
- Pascal Soriot
- Employees
- 96,100
United Airlines
- Founded
- 1926
- Headquarters
- Chicago, Illinois
- Current CEO
- Scott Kirby
- Employees
- 113,200
Founders
AstraZeneca
Sir David Barnes
Sir David Barnes was chief executive of Zeneca Group plc, the company created when Imperial Chemical Industries demerged its pharmaceuticals, agrochemicals and specialty chemicals businesses in 1993, and he led the Zeneca side of the negotiations that produced…
Håkan Mogren
Håkan Mogren was chief executive of Astra AB and negotiated the Swedish side of the 1999 merger with Zeneca Group alongside Sir David Barnes.
United Airlines
Walter T. Varney
Walter T. Varney founded Varney Air Lines, which won Contract Air Mail Route 5 and flew its first route between Pasco, Washington, and Elko, Nevada, via Boise, on April 6, 1926.
William Boeing
William Boeing formed Boeing Air Transport in 1927 to fly the Chicago-San Francisco air mail route and then, with Frederick Rentschler, created United Aircraft and Transport Corporation in 1929.
CEOs and their tenures
AstraZeneca
- Tom McKillop1999–2006
Chief Executive Officer
McKillop led AstraZeneca from the 1999 merger through the Nexium launch and the first biotech acquisitions.
Source - David Brennan2006–2012
Chief Executive Officer
Brennan led AstraZeneca through the start of the patent cliff and favoured cost-cutting and share buybacks over pipeline investment.
Source - Pascal Soriot2012–present
Chief Executive Officer
Soriot took over a company whose revenue was falling toward $25.7 billion and has taken Total Revenue to $58.7 billion, with 16 blockbuster medicines.
Source
United Airlines
- Oscar Munoz2015–2020
Former CEO
Munoz handed over to Scott Kirby in May 2020 and served as executive chairman for a transition period.
Source - J. Scott Kirby2020–present
Chief Executive Officer
Under Kirby, United's revenue rose from $15.4 billion in 2020 to a record $59.1 billion in 2025, with premium cabins and MileagePlus as the main growth drivers.
Source
Timeline: AstraZeneca and United Airlines side by side
1913AstraZeneca
Astra AB Founded in Södertälje, Sweden
400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.
1926United Airlines
Varney Air Lines begins
United traces its roots to Varney Air Lines and early air mail service.
1931United Airlines
United Air Lines organized
United Air Lines was formed to manage airline subsidiaries tied to United Aircraft and Transport.
1993AstraZeneca
Zeneca Group Spun Off from ICI
Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.
1997United Airlines
Star Alliance founded
United became one of the founding members of Star Alliance.
1999AstraZeneca
Astra and Zeneca Merge to Form AstraZeneca
The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.
2000AstraZeneca
Nexium Launch Replaces Prilosec
AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.
2006AstraZeneca
Acquisition of Cambridge Antibody Technology
AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.
2007AstraZeneca
Acquisition of MedImmune for $15.6 Billion
AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.
2010United Airlines
Continental merger closes
UAL Corporation completed the Continental merger, later operating under the United brand.
2012AstraZeneca
Pascal Soriot Appointed CEO
Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.
2014AstraZeneca
Pfizer Hostile Takeover Rejected
AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.
2014AstraZeneca
Acquisition of Almirall Respiratory Portfolio
AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.
2015AstraZeneca
Tagrisso Approved for EGFR-Mutated Lung Cancer
The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.
2015United Airlines
Oscar Munoz becomes CEO
Oscar Munoz became chief executive of United in September 2015.
2017AstraZeneca
Imfinzi Approved Based on PACIFIC Trial
The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.
2020AstraZeneca
COVID-19 Vaccine Development with Oxford University
AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.
2020United Airlines
Scott Kirby becomes CEO
Scott Kirby succeeded Oscar Munoz as CEO in May 2020.
2021AstraZeneca
Acquisition of Alexion Pharmaceuticals for $39 Billion
AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.
2023AstraZeneca
CinCor Pharma Acquired for up to $1.8 Billion
AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.
2024AstraZeneca
Total Revenue Reaches $54.073 Billion
AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.
2024AstraZeneca
Fusion Pharmaceuticals and Gracell Acquisitions
AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.
2025AstraZeneca
Total Revenue Reaches $58.739 Billion
AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.
2025AstraZeneca
EsoBiotec Acquired for Up to $1 Billion
AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.
2025AstraZeneca
$50 Billion US Manufacturing and R&D Commitment
AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.
2025United Airlines
Revenue reaches record level
United reported record 2025 total operating revenue of $59.1 billion.
2026AstraZeneca
Ordinary Shares Begin Trading on the NYSE
AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.
2026AstraZeneca
Baxfendy Approved in the US for Hypertension
The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.
2026AstraZeneca
$15 Billion China Investment Through 2030
AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.
2026United Airlines
Q2 2026 revenue up 16%
United reported Q2 2026 revenue of $17.7 billion and raised full-year adjusted EPS guidance to $9-$11 despite nearly $6 billion in added fuel costs.
Acquisitions
AstraZeneca
- EsoBiotec2025$1B
- Fusion Pharmaceuticals2024$2B
- Gracell Biotechnologies2024$1.2B
- CinCor Pharma2023$1.8B
- Alexion Pharmaceuticals2021$39B
- Almirall Respiratory Portfolio2014$2.1B
Questions about AstraZeneca vs United Airlines
Who is the CEO of AstraZeneca PLC and United Airlines Holdings, Inc.?
AstraZeneca PLC is led by Pascal Soriot and United Airlines Holdings, Inc. is led by Scott Kirby. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AstraZeneca PLC founded vs United Airlines Holdings, Inc.?
United Airlines Holdings, Inc. was founded in 1926 — 73 years before AstraZeneca PLC, which was founded in 1999. United Airlines Holdings, Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AstraZeneca PLC.
How many employees does AstraZeneca PLC have compared to United Airlines Holdings, Inc.?
AstraZeneca PLC employs approximately 96,100 people, while United Airlines Holdings, Inc. employs approximately 113,200. United Airlines Holdings, Inc. has the larger workforce at 113,200 employees, compared to AstraZeneca PLC's 96,100. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AstraZeneca PLC and United Airlines Holdings, Inc. headquartered?
AstraZeneca PLC is headquartered in United Kingdom and United Airlines Holdings, Inc. is headquartered in United States. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AstraZeneca PLC and United Airlines Holdings, Inc.?
AstraZeneca PLC was founded by Sir David Barnes, Håkan Mogren. United Airlines Holdings, Inc. was founded by Walter T. Varney, William Boeing.
Which company has a longer operating history — AstraZeneca PLC or United Airlines Holdings, Inc.?
United Airlines Holdings, Inc. has been operating for approximately 100 years, making it the more established of the two companies. AstraZeneca PLC has been in operation for around 27 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AstraZeneca vs United Airlines overview